NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
2023年5月23日 - 5:01AM
NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing
a novel approach to immunotherapy designed to orchestrate a
targeted immune response by directing the function of
antigen-specific T cells in oncology, autoimmune and infectious
diseases, today announced that it will be presenting a poster at
the Federation of Clinical Immunology Societies (FOCIS) Annual
Meeting, being held in Boston from June 20-23, 2023.
This poster is a result of a collaboration
between NexImmune and Dr. Steven Jacobsen at the NIH which is
focused on two goals. The first is to use NexImmune’s AIM
nanoparticle technology to expand and characterize EBV specific
CD8+ T cells from healthy and multiple sclerosis (MS) donors to
assess whether MS may be associated with defective T cell control
of EBV-infected B cells. The second goal is to evaluate whether
specific T cell defects can be circumvented as a potential
development strategy to enable CD8+ specific killing of EBV+ cells
that are believed to be a significant contributing factor to
multiple sclerosis.
“As the data and recent publications indicate,
there is an increasing level of focus on the role of EBV and the
importance of T cell responses in diseases such as MS,” said Dr.
Jack Ragheb, Senior Vice President of Translational Sciences and
Medicine at NexImmune. “We believe AIM products are uniquely
positioned to deliver multi-antigen targeted approaches to address
unmet need in these disease areas.”
Poster Presentation:
Title: “Expansion of EBV
Peptide-Specific CD8 T Cells from Multiple Sclerosis Patients and
Healthy Donors Reveals Dysregulation of Effector Responses that may
be Associated with Disease Pathogenesis”
Abstract #: 1515606
Authors: Jack A. Ragheb1,
William Frazier2, Lauren Suarez1, Maria Monaco-Kushner2, Ruipeng
Wang1, Mathias Oelke1, Steven Jacobson2
1NexImmune, Inc.2VID, NINDS, NIH
About NexImmune
NexImmune is a clinical-stage biotechnology
company developing a novel approach to immunotherapy designed to
employ the body’s own T cells to generate a specific, potent, and
durable immune response. The backbone of NexImmune’s approach is a
proprietary Artificial Immune Modulation (AIM™) nanoparticle
technology platform. The AIM technology enables NexImmune to
construct nanoparticles that function as synthetic dendritic cells
capable of directing a specific T cell-mediated immune response.
AIM constructed nanoparticles employ natural biology to engage,
activate and expand endogenous T cells in ways that combine
anti-tumor attributes of antigen-specific precision, potency and
long-term persistence with reduced potential for off-target
toxicities. NexImmune is focused on developing injectable AIM
nanoparticle constructs and modalities for potential clinical
evaluation in oncology, autoimmune disorders and infectious
diseases.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking”
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are based on the beliefs and assumptions
and on information currently available to management of NexImmune,
Inc. (the “Company”). All statements other than statements of
historical fact contained in this press release are forward-looking
statements, including statements concerning the enrollment, timing,
progress, release of data from and results of the Company’s paused
clinical trials and the expectations with respect to potential AIM
INJ product candidates; the timing, progress and release of
preclinical data from our AIM INJ platform programs and other
preclinical research programs; and the utility of prior preclinical
and clinical data in determining future clinical results. In some
cases, you can identify forward-looking statements by terminology
such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of these terms or other comparable terminology.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties set forth in the “Risk Factors” section of our Annual
Report on Form 10-K for the year ended December 31, 2022 filed
with the Securities and Exchange Commission (“SEC”) on
March 28, 2023, and subsequent reports that we file with the
SEC. Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Although the
Company believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee
future results, levels of activity, performance or achievements.
Except as required by law, the Company assumes no obligation to
publicly update any forward-looking statements for any reason after
the date of this press release to conform any of the
forward-looking statements to actual results or to changes in its
expectations.
ContactsInvestors and
Media:Chad Rubin, SVP Corporate Affairs and Investor
RelationsNexImmune, Inc.crubin@neximmune.com
NexImmune (NASDAQ:NEXI)
過去 株価チャート
から 4 2024 まで 5 2024
NexImmune (NASDAQ:NEXI)
過去 株価チャート
から 5 2023 まで 5 2024